BR0214048A - 1,4-benzodiazepinas substituìdas e seus usos para o tratamento de câncer - Google Patents

1,4-benzodiazepinas substituìdas e seus usos para o tratamento de câncer

Info

Publication number
BR0214048A
BR0214048A BR0214048-9A BR0214048A BR0214048A BR 0214048 A BR0214048 A BR 0214048A BR 0214048 A BR0214048 A BR 0214048A BR 0214048 A BR0214048 A BR 0214048A
Authority
BR
Brazil
Prior art keywords
optionally substituted
cycloalkyl
heteroaryl
aralkyl
aryl
Prior art date
Application number
BR0214048-9A
Other languages
English (en)
Inventor
Tianbao Lu
Louis V Lafrance
Iii
Daniel J Parks
Karen L Milkiewicz
Raul R Calvo
Maxwell David Cummings
Alexander J Kim
Bruce L Grasberger
Theodore E Carver
Original Assignee
Dimensional Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimensional Pharm Inc filed Critical Dimensional Pharm Inc
Publication of BR0214048A publication Critical patent/BR0214048A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

"1,4-BENZODIAZEPINAS SUBSTITUìDAS E SEUS USOS PARA O TRATAMENTO DE CâNCER". A presente invenção e voltada a 1,4-benzodiazipinas inéditas, a composições farmacêuticas suas e ao seu uso como inibidores de interações de HDM2-p53. Os compostos têm a fórmula (I) ou um solvato, hidrato ou sal seu farmaceuticamente aceitável, em que X e Y são independentemente -C(O)-, -CH~ 2~- ou -C(S)-; R^ 1^, R^ 2^, R^ 3^, R^ 4^, R^ 7^, R^ 8', R^ b^, R^ c^, R^ d^ e M são definidos no presente. R^ 5^ é hidrogênio, alquila, cicloalquila, arila opcionalmente substituído, heteroarila opcionalmente substituído, aralquila opcionalmente substituído, heteroarila opcionalmente substituído, carbóxialquila, alcóxi-carbonila, alcóxi-alquila, amino-carbonila, amino-carbonil-alquila, alquilamino-carbonila ou alquilamino-carbonil-alquila; R^ 6^ é cicloalquila, arila, heteroarila, cicloalquil-alquila, aralquila, heteroaril-alquila ou um heterociclo saturado ou parcialmente insaturado, sendo cada um deles opcionalmente substituído; R^ 9^ é cicloalquila, arila, heteroarila, um heterociclo saturado ou parcialmente insaturado, cicloalquil-(alquila), aralquila ou heteroarilalquila, sendo cada um deles opcionalmente substituído; e R^ 10^ é - (CH~ 2~)~ n~-CO~ 2~R^ b^, - (CH~ 2~)~ m~CO~ 2~M,-(CH~ 2~)~ i~-OH ou - (CH~ 2~)~ j~ -CONR^ c^R^ d^; n é 0-8, m é 0-8, i é 1-8, j é 0-8.
BR0214048-9A 2001-11-13 2002-11-13 1,4-benzodiazepinas substituìdas e seus usos para o tratamento de câncer BR0214048A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33123501P 2001-11-13 2001-11-13
PCT/US2002/036208 WO2003041715A1 (en) 2001-11-13 2002-11-13 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR0214048A true BR0214048A (pt) 2004-10-13

Family

ID=23293137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214048-9A BR0214048A (pt) 2001-11-13 2002-11-13 1,4-benzodiazepinas substituìdas e seus usos para o tratamento de câncer

Country Status (26)

Country Link
US (2) US7067512B2 (pt)
EP (1) EP1443937B1 (pt)
JP (1) JP4497921B2 (pt)
KR (1) KR20050044413A (pt)
CN (1) CN1596114A (pt)
AT (1) ATE398453T1 (pt)
AU (1) AU2002340464B2 (pt)
BR (1) BR0214048A (pt)
CA (1) CA2466055A1 (pt)
CY (1) CY1108352T1 (pt)
DE (1) DE60227185D1 (pt)
DK (1) DK1443937T3 (pt)
ES (1) ES2309209T3 (pt)
HR (1) HRP20040415A2 (pt)
HU (1) HUP0402003A3 (pt)
IL (1) IL161692A0 (pt)
MX (1) MXPA04004500A (pt)
NO (1) NO20042146L (pt)
NZ (1) NZ532463A (pt)
PL (1) PL370176A1 (pt)
PT (1) PT1443937E (pt)
RU (1) RU2004118243A (pt)
SI (1) SI1443937T1 (pt)
UA (1) UA76798C2 (pt)
WO (1) WO2003041715A1 (pt)
ZA (1) ZA200403082B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197893A1 (en) * 2002-10-16 2004-10-07 Carsten Schubert HDM2-inhibitor complexes and uses thereof
US20050227932A1 (en) * 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US7358241B2 (en) * 2003-01-21 2008-04-15 Thallion Pharmaceuticals, Inc. Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions
US7186713B2 (en) 2003-01-21 2007-03-06 Ecopia Biosciences, Inc. Farnesyl dibenzodiazepinones and methods of treating cancer using same
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
DE112004001191B4 (de) * 2003-07-02 2017-11-09 Corus Pharma Inc. Verfahren zur Herstellung des L-Lysin-Salzes von Aztreonam und Verfahren zur Bestimmung des Verunreinigungsgrads in einem amorphen Aztreonam Lysin-Salz
CA2577060A1 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
SG155941A1 (en) 2004-09-22 2009-10-29 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
WO2006035051A1 (en) 2004-09-28 2006-04-06 Janssen Pharmaceutica N.V. A bacterial atp synthase binding domain
US7763604B2 (en) * 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
EP1948191B1 (en) * 2005-11-01 2013-01-16 The Regents of the University of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
AU2007228784B2 (en) 2006-03-22 2012-03-08 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53
US8470785B2 (en) 2006-07-28 2013-06-25 St. Jude Children's Research Hospital Method for treating ocular cancer
US8614192B2 (en) 2006-07-28 2013-12-24 Leiden University Medical Center Method for treating ocular cancer
WO2008072655A1 (ja) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited イミダゾチアゾール誘導体
TWI539947B (zh) 2007-04-09 2016-07-01 米希爾金尼公司 組蛋白去乙醯基酶之抑制劑
NZ580801A (en) * 2007-05-10 2012-09-28 Bristol Myers Squibb Co Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2008144981A1 (fr) * 2007-05-25 2008-12-04 Topharman Shanghai Co., Ltd. Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine
JP5539864B2 (ja) * 2007-06-12 2014-07-02 アカオゲン，インコーポレーテッド 抗菌剤
US8853406B2 (en) 2007-08-06 2014-10-07 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53
AR070449A1 (es) * 2008-02-22 2010-04-07 Otsuka Pharma Co Ltd Compuesto de benzodiazepina y composicion farmaceutica
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
MX2011008195A (es) 2009-02-04 2011-09-06 Janssen Pharmaceutica Nv Derivados de indol como agentes anticancer.
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
CN102321034B (zh) * 2011-06-07 2014-08-13 中国人民解放军第二军医大学 硫代苯二氮卓类化合物及其作为药物的用途
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
CN105693634B (zh) * 2016-03-17 2018-12-11 清华大学 化合物及其用途
US10669242B2 (en) * 2016-06-10 2020-06-02 Venenum Biodesign, LLC Clostridium difficile toxin inhibitors
US10583193B2 (en) 2017-01-25 2020-03-10 Sorrento Therapeutics, Inc. Cell penetrating peptide inhibitors of p53-MDM2 interaction
CN110317294B (zh) * 2018-03-30 2021-06-18 长春理工大学 一种三苯胺类温敏荧光聚合物及其制备方法
CN111995576A (zh) * 2020-08-31 2020-11-27 三峡大学 多取代含氮杂环化合物的制备方法
TW202345852A (zh) * 2022-03-16 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環類化合物、其製備方法及其在醫藥上的應用
CN117263873A (zh) * 2022-06-15 2023-12-22 复旦大学 1,4-苯二氮䓬类化合物及其在制备抗肿瘤药物中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5389631A (en) 1991-10-29 1995-02-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
US5441952A (en) 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH09511998A (ja) 1994-04-15 1997-12-02 グラクソ、ウェルカム、インコーポレーテッド １，４ − ベンゾジアゼピン化合物を用いたコレシストキニンアゴニスト活性の誘導方法
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
PL342254A1 (en) 1998-01-29 2001-06-04 Aventis Pharm Prod Inc Method of obtaining n-[(aliphatic or aromatic substituend)carbonyl)]-2-aminacetamide and cyclised compound
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
WO2000056721A1 (en) 1999-03-23 2000-09-28 Axys Pharmaceuticals, Inc. Solid phase synthesis of benzodiazepine diones
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
JP5127096B2 (ja) 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
US6600016B1 (en) * 1999-08-24 2003-07-29 Advanced Syntech Llc Multifunctionalized solid support resins for synthesis of combinatorial libraries and method for using the same
WO2001055121A1 (fr) * 2000-01-28 2001-08-02 Kaken Pharmaceutical Co., Ltd. Dérivés d'azépine

Also Published As

Publication number Publication date
RU2004118243A (ru) 2006-01-10
MXPA04004500A (es) 2004-08-11
CA2466055A1 (en) 2003-05-22
PL370176A1 (en) 2005-05-16
US7067512B2 (en) 2006-06-27
SI1443937T1 (sl) 2009-02-28
HUP0402003A3 (en) 2005-06-28
HUP0402003A2 (hu) 2005-02-28
US20030109518A1 (en) 2003-06-12
PT1443937E (pt) 2008-09-23
NO20042146L (no) 2004-08-11
DK1443937T3 (da) 2008-10-20
KR20050044413A (ko) 2005-05-12
UA76798C2 (uk) 2006-09-15
US20060148792A1 (en) 2006-07-06
EP1443937B1 (en) 2008-06-18
HRP20040415A2 (en) 2005-04-30
DE60227185D1 (de) 2008-07-31
CN1596114A (zh) 2005-03-16
CY1108352T1 (el) 2014-02-12
WO2003041715A1 (en) 2003-05-22
IL161692A0 (en) 2004-09-27
JP2005509005A (ja) 2005-04-07
ZA200403082B (en) 2005-04-22
ES2309209T3 (es) 2008-12-16
AU2002340464B2 (en) 2008-03-13
ATE398453T1 (de) 2008-07-15
NZ532463A (en) 2007-02-23
JP4497921B2 (ja) 2010-07-07
EP1443937A1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
BR0214048A (pt) 1,4-benzodiazepinas substituìdas e seus usos para o tratamento de câncer
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BRPI0407283A (pt) Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
GB0022438D0 (en) Organic Compounds
CY1115171T1 (el) Ιατρικο φαρμακο
IN2012DN01325A (pt)
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
HK1138262A1 (en) Novel phosphodiesterase inhibitors
NZ606539A (en) Use of sigma ligands in opioid-induced hyperalgesia
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
WO2009087379A3 (en) Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
BR0311960A (pt) Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica
TW200616635A (en) Novel compounds
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
ATE254098T1 (de) Verbindungen die die tryptase-activität hemmen
GEP20115240B (en) Indole derivatives, process for their preparation and pharmaceutical compositions containing them
BRPI0412438A (pt) novas amidas aza-heterocìclicas úteis para o tratamento da dor
UA98639C2 (en) Phosphodiesterase inhibitors
TW200621227A (en) Medicament for preventing or treating fatty liver
HK1049169B (zh) 取代的4-苄基氨基喹啉、其製備方法、含有這些化合物的藥物及其應用

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.